ClinicalTrials.gg
Active, not recruitingNCT05054439Updated Sep 1, 2026

A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC

A Phase 2 interventional study of SI-B001 and Paclitaxel in Head and Neck Squamous Cell Carcinoma, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Active, not recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Squamous Cell Carcinoma of Head and Neck by Sichuan Biokin Pharmaceutical Co., Ltd. — 7 open to participants now, 12 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Sichuan Biokin Pharmaceutical Co., Ltd..

Enrollment
7th of 12
45 · median 46
Started
2021
with 1 other
Phase 2
6 of 12
3 open now
Primary completion
2026-12
later than 4 of 11 live
Registered
2nd of 12
by date

Among the 12 studies in Squamous Cell Carcinoma of Head and Neck by Sichuan Biokin Pharmaceutical Co., Ltd., this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 2nd registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

7 of the 12 studies in Squamous Cell Carcinoma of Head and Neck by Sichuan Biokin Pharmaceutical Co., Ltd. are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Squamous Cell Carcinoma of Head and Neck by Sichuan Biokin Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

This Phase IIa study is a clinical trial to evaluate the safety and efficacy of SI-B001 in combination with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) who have experienced disease progression or intolerance to prior anti-PD-1 monoclonal antibody therapy with or without platinum-based chemotherapy, and who have received no more than second-line treatment.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participants could understand and sign the form and must participate voluntarily.
  2. No gender limit;
  3. Age: ≥18 years old
  4. Locally advanced squamous cell carcinoma of the head and neck confirmed by histology or pathology as recurrent or without indications of radical local treatment;
  5. Patients who have failed or are intolerant to prior monotherapy ± platinum-based chemotherapy; Cohort-A: Patients with recurrent/metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) who have progressed on or are intolerant to anti-PD-1/PD-L1 antibody ± platinum-based doublet chemotherapy, receiving SI-B001 in combination with paclitaxel/docetaxel in the second-line setting (patients with no prior treatment with docetaxel, paclitaxel, nab-paclitaxel, or paclitaxel liposome receive paclitaxel in combination; patients with prior docetaxel treatment receive paclitaxel in combination; patients with prior treatment with paclitaxel, nab-paclitaxel, or paclitaxel liposome receive docetaxel in combination).

    Cohort-B: Patients with recurrent/metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) who have progressed on or are intolerant to first-line platinum-based doublet chemotherapy ± EGFR monoclonal antibody, and subsequently progressed on or are intolerant to second-line anti-PD-1/PD-L1 monoclonal antibody-containing therapy, receiving SI-B001 in combination with paclitaxel/docetaxel in the third-line setting (patients with no prior treatment with docetaxel, paclitaxel, nab-paclitaxel, or paclitaxel liposome receive paclitaxel in combination; patients with prior docetaxel treatment receive paclitaxel in combination; patients with prior treatment with paclitaxel, nab-paclitaxel, or paclitaxel liposome receive docetaxel in combination).

  6. Previously received only ≤ 2-line treatment for recurrent and metastatic squamous cell carcinoma of the head and neck;
  7. Agree to provide tumor tissue samples (FFPE block or 10 unstained sections of 5μm size) or fresh tissue samples that have been archival within 1 year of primary or metastatic lesion. If the patient fails to provide them, they can be included after the investigator's judgment;
  8. There must be at least one in accordance with the V1.1 definition. Tumor lesions located in the area of previous radiotherapy or other local regional treatment sites are generally not measurable unless there is definite progression of the lesion or the lesion persists three months after radiotherapy;
  9. Physical fitness score 0 or 1;
  10. Toxicity of previous antitumor therapy has returned to ≤1 as defined by V5.0 (except for toxicity that the investigators judged to be of no safety risk, such as hair loss, grade 2 peripheral neurotoxicity, and stabilized hypothyroidism after hormone replacement therapy);
  11. Organ function levels must meet the following requirements and meet the following standards:

    1. Bone marrow function: (ANC)≥1.5×10*9/L, count ≥100×10*9/L, ≥90 g/L;
    2. Liver function: Total TBIL≤1.5× (total bilirubin ≤3×ULN in Subjects with Gilbert's syndrome, liver cancer or liver metastasis), and ALT ≤2.5×ULN in patients without liver metastasis, AST and ALT ≤5.0×ULN in patients with liver metastasis;
    3. Renal function: creatinine (Cr) ≤1.5×ULN, or (Ccr) ≥50 mL/min (according to Cockcroft and Gault formula);
    4. Urine routine / 24-hour protein quantification: qualitative urine protein ≤1+ (if qualitative urine protein ≥2+, 24-hour protein \< 1g can be included in the group);
    5. Cardiac function: ≥50%;
    6. Coagulation function: International standardized ratio () ≤1.5×ULN, and activated partial thrombin time (APTT) ≤1.5×ULN;
  12. Eligible patients (male and female) who are fertile must agree to use a reliable method (hormonal or barrier method or abstinence, etc.) with their partner during the trial and for at least 6 months after the last medication; women of childbearing age must have a negative blood or urine pregnancy test within 7 days prior to the first use of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Squamous cell carcinoma of primary origin in the nasopharynx, salivary glands, paranasal sinuses, skin, or of unknown primary site;
  2. Have received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor therapy within 4 weeks prior to the first use of the study drug, except the following:

    • Nitrosorea or mitomycin C within 6 weeks before the first administration of the study drug;
    • Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first administration of the study drug or within the 5 half-lives of the drug (whichever is longer);
    • The traditional Chinese medicines with anti-tumor indications were within 2 weeks before the first use of the study drug;
  3. Received an unmarketed clinical drug or treatment within 4 weeks prior to the first use of the investigational drug;
  4. Has undergone major organ surgery (excluding needle , tracheotomy, gastrostomy, etc.) or has significant trauma within 4 weeks before the first use of study drugs, or needs to undergo elective surgery during the trial;
  5. Patients who have previously been treated with paclitaxel, nab-paclitaxel, liposomal paclitaxel, and docetaxel;
  6. Previous recipients of hematopoietic stem cell transplantation or organ transplantation;
  7. A history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

    • Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade iii atrioventricular block, etc.
    • In the resting state, was prolonged (QTc > 450 msec in men or QTc > 470 msec in women).
    • Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grades 3 or higher cardio-cerebrovascular events within 6 months prior to the first administration;
    • (NYHA) heart function grade ≥II heart failure;
  8. Active diseases and inflammatory diseases, such as systemic lupus erythematosus, systemic treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and Hashimoto's thyroiditis, etc., with the exception of type I diabetes, only replacement therapy can control hypothyroidism, no systemic treatment of skin disease (e.g., vitiligo, psoriasis);
  9. A history of other within 5 years prior to first administration, except for radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or radical excised carcinoma in place, and second primary squamous cell carcinoma of the head and neck;
  10. Poorly controlled hypertension (systolic blood pressure \& GT; 150 mmHg or diastolic pressure > 100 mmHg);
  11. Pulmonary disease defined as grade 3 or higher according to V5.0; Patients with past or present interstitial lung disease (ILD);
  12. Cerebral parenchymal or meningeal with clinical symptoms are not suitable for inclusion by the investigator;
  13. Experienced ≥ grade 3 infusion-related reactions during previous anti-EGFR antibody therapy;
  14. Known allergies to paclitaxel or its standard pretreatments or other to products containing castor oil;
  15. antibody (HIVAb) positive, active tuberculosis, active virus infection (HBV-DNA copy number > 104) or virus infection (HCV-RNA > center detection lower limit);
  16. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.;
  17. Pregnant or lactating women;
  18. Persons with mental disorders or poor compliance;
  19. The investigator considers that the subject has a history of other serious systemic diseases or other reasons and is not suitable to participate in this clinical study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    SI-B001 combined with paclitaxel or docetaxel

    SI-B001 in combination with paclitaxel or docetaxel for the treatment of recurrent metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) with disease progression or intolerance. The patient had previously received anti-PD-1 mab ± platinum-based chemotherapy. Patients' previous treatment line should be ≤2L.

    Drug: SI-B001 · Drug: Paclitaxel · Drug: docetaxel

Interventions

  • Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.

  • The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.

  • Docetaxel is administered at a dose of 35 mg/m² on Days 1, 8, and 15, with a 4-week treatment cycle. Treatment is continued until disease progression, unacceptable toxicity, or other reasons for discontinuation (such as withdrawal of informed consent or death).

06

What researchers measure

Primary outcomes

  1. ORR

    (Objective Response Rate )

    Time frame: Up to 2 years

Secondary outcomes

  1. IRC-assessed Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

    Time frame: Up to 2 years

  2. PFS

    Progression-free Survival

    Time frame: Up to 2 years

  3. DCR

    Disease Control Rate

    Time frame: Up to 2 years

  4. Duration of Response (DOR)

    Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.

    Time frame: Up to 2 years

  5. OS

    overall survival

    Time frame: Up to 2 years

  6. TEAE

    Treatment Emergent Adverse Events

    Time frame: Up to 2 years

  7. Cmax

    maximum serum concentration

    Time frame: Up to 2 years

  8. Tmax

    Time to maximum serum concentration

    Time frame: Up to 2 weeks

  9. Ctrough

    Minimum serum concentration

    Time frame: Up to 2 years

  10. ADA

    anti-SI-B001 antibody

    Time frame: Up to 2 years

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 60 months is above that.

Counting every sponsor, half of 365 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2021
First posted
Sep 23, 2021
StartActual
Dec 22, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05054439
Responsible party
Sponsor
First posted
Sep 23, 2021
Start date
Dec 22, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izalontamab

Start the discussion